SCHEDULE: Franklin Resources Discloses 6.5% Stake in Adicet Bio

Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. have reported a 6.5% beneficial ownership stake in Adicet Bio, Inc. as of December 31, 2025.

Summary

• Franklin Resources, Inc., a Delaware corporation, and its subsidiary Franklin Advisers, Inc., a California corporation, have filed a Schedule 13G regarding their beneficial ownership in Adicet Bio, Inc.
• As of December 31, 2025, Franklin Advisers, Inc. beneficially owns 626,571 shares of Adicet Bio, Inc. common stock, representing 6.5% of the class.
• Franklin Advisers, Inc. holds sole voting power and sole dispositive power over these 626,571 shares.
• Franklin Resources, Inc., as the parent holding company, aggregates this ownership for reporting purposes, while the direct investment and voting discretion reside with Franklin Advisers, Inc. on behalf of its clients.
• Charles B. Johnson and Rupert H. Johnson, Jr., principal stockholders of Franklin Resources, Inc., are also listed as reporting persons but report 0 beneficial ownership directly.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Adicet Bio, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by a reputable institutional investor like Franklin Resources can imply a degree of confidence in Adicet Bio's value proposition, even if the investment is passive.

Positives

• A significant institutional investor, Franklin Resources, Inc. (through Franklin Advisers, Inc.), holds a 6.5% stake, which can be interpreted as a vote of confidence in Adicet Bio, Inc.'s long-term prospects.

Risks

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, mitigating a potential risk of activist investor intervention.
• Franklin Resources, Inc., the Principal Shareholders, and Investment Management Subsidiaries disclaim being a 'group' within the meaning of Rule 13d-5, which could otherwise imply coordinated action and potential control issues.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
• The clients of the Investment Management Subsidiaries, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, the securities reported herein.
• FRI, the Principal Shareholders and each of the Investment Management Subsidiaries disclaim any pecuniary interest in any of such securities.
• FRI, the Principal Shareholders, and each of the Investment Management Subsidiaries believe that they are not a 'group' within the meaning of Rule 13d-5 under the Act and that they are not otherwise required to attribute to each other the beneficial ownership of the securities held by any of them or by any persons or entities for whom or for which the Investment Management Subsidiaries provide investment management services.

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by a major asset manager like Franklin Resources in a biotechnology company like Adicet Bio can signal institutional confidence in the company's long-term prospects or its specific therapeutic pipeline. Such filings are common for large investment firms managing diverse portfolios.

Comparison to Industry Standards

• A 6.5% stake by a major institutional investor like Franklin Resources is a substantial position, often indicating a long-term investment horizon. This level of ownership is typical for passive institutional investors reporting under Schedule 13G, similar to stakes held by diversified asset managers like BlackRock or Vanguard in numerous public companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence among existing shareholders and attract new investors, potentially stabilizing or positively influencing the stock price.
• Management: Management may view this as validation of their strategy and operations, though the passive nature of the investment suggests no immediate pressure for strategic changes.

Next Steps

• Franklin Resources, Inc. and its affiliates will continue to monitor their investment in Adicet Bio, Inc.
• Future Schedule 13G/A or 13D filings would be required if their beneficial ownership changes significantly (e.g., crosses 10% or if investment intent changes to active influence).

Key Dates

Recommendation

The filing indicates a significant, passive institutional investment by Franklin Resources in Adicet Bio. While this suggests a vote of confidence from a major asset manager, the filing itself does not provide new operational or financial performance data for Adicet Bio that would warrant a 'buy' or 'sell' recommendation. It primarily confirms a substantial existing stake held for investment purposes in the ordinary course of business. Therefore, a 'hold' recommendation is appropriate, pending further analysis of Adicet Bio's fundamental performance and strategic developments.

Keywords

Adicet Bio, Franklin Resources, Franklin Advisers, beneficial ownership, institutional investor, Schedule 13G, biotechnology, common stock, SEC filing, investment management